| Study | Reason for exclusion |
|---|---|
| Aalbers 2012 | Study design (no RCT) |
| Abdel‐Salam 2015 | Type of participants (focus on cardiomyopathy, not heart failure alone) |
| Adamyan 2010 | Study design (no RCT) |
| Adamyan 2011 | Type of intervention (comparator BB, not placebo or SC) |
| Adamyan 2013 | Type of intervention (comparator BB, not placebo or SC) |
| Adamyan 2015b | Type of participants (focus on atrial fibrillation, not heart failure) |
| Al 2013 | Study design (no RCT) |
| Amosova 2011a | Study design (no RCT) |
| Amosova 2011b | Study design (no RCT) |
| Amosova 2012a | Study design (no RCT) |
| Amosova 2012b | Study design (no RCT) |
| Amosova 2014 | Study design (no RCT) |
| Cavusoglu 2012 | Type of intervention (ivabradine plus dobutamine) |
| Cavusoglu 2015 | Type of intervention (ivabradine plus dobutamine) |
| Chumburidze 2013 | Study design (no RCT) |
| CN‐01908706 2018 | Types of participants |
| Cocco 2013 | Type of intervention (comparator BB, not placebo or SC) |
| Cullington 2011 | Study design (no RCT) |
| De 2014 | Study design (no RCT) |
| De Ferrari 2008 | Study design (no RCT) |
| EUCTR2011‐002520‐40‐IT | Prematurely ended |
| Fomin 2016 | Type of intervention (comparator BB, not placebo or SC) |
| Gallet 2014 | Study design (no RCT) |
| Gurcagan 2015 | Study design (no RCT) |
| Hidalgo 2015a | Study design (no RCT) |
| Hidalgo 2015b | Study design (no RCT) |
| Hidalgo 2016a | Study design (no RCT) |
| Hidalgo 2016b | Study design (no RCT) |
| Hidalgo 2018 | Study design (no RCT) |
| Iliuta 2014 | Study design (no RCT) |
| Kanorsky 2016 | Type of intervention (comparator BB, not placebo or SC) |
| Kosheleva 2010 | Type of participants (focus on congestive heart failure) |
| Lofrano‐Alves 2015 | Study design (no RCT) |
| Lutay 2012 | Type of participants (focus on myocardial infarction) |
| Mansour 2011 | Type of participants (focus on cardiomyopathy, not heart failure alone) |
| Mert 2017 | Study design (no RCT) |
| Nguyen 2017 | Study design (no RCT) |
| Ozturk 2016 | Study design (no RCT) |
| Pal 2015 | Study design (cross‐over study with hypertensive volunteers) |
| Raja 2011 | Type of participants (focus on myocardial infarction) |
| Raja 2018 | Type of participants (focus on cardiomyopathy, not heart failure alone) |
| Rajagopal 2010 | Study design (no RCT) |
| Reil 2012 | Study design (no RCT) |
| Riccioni 2012 | Type of intervention (comparator BB, not placebo or SC) |
| Sallam 2016 | Study design (no RCT) |
| Santos 2014 | Study design (no RCT) |
| Sisakian 2014 | Study design (no RCT) ("empirically allocated") |
| Tagliamonte 2016 | Study design (no RCT) |
| Tregubov 2015 | Type of intervention (comparator BB, not placebo or SC) |
| Tumasyan 2009 | Type of participants (focus on cardiomyopathy, not heart failure alone) |
| Vatinian 2015 | Study design (no RCT) |
| Volterrani 2011 | Type of intervention (comparator BB, not placebo or SC) |
| Xu 2011 | Type of intervention (comparator BB, not placebo or SC) |
| Yao 2014 | Study design (no RCT) |
BB = beta‐blocker, RCT = randomised controlled trial, SC = standard care